ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1

Total Enrollment

610 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-04-26

Study Completion Date

2028-05-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. The objectives of this study are to investigate the safety, tolerability, pharmacokinetics and anti-tumor activity of HS-20093 in combination with other anti-cancer agents in patients with advanced solid tumor patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

ARTEMIS-001: Phase 1 Study of the HS-20093 in Patients With Advanced Solid Tumors

NCT05276609

Advanced Solid Tumor

UNKNOWN PHASE1

A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors

NCT06417554

Advanced Solid Tumors

RECRUITING PHASE1/PHASE2

A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors

NCT06594874

Non-Small Cell Lung Cancer Advanced Solid Tumors

NOT_YET_RECRUITING PHASE1

Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors

NCT06621563

Solid Tumors Non-Small Cell Lung Cancer Colorectal Cancer

RECRUITING PHASE1

A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma

NCT06738251

Advanced Urothelial Carcinoma

RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a phase 1, open-label, multi-center, dose-escalation and expansion, phase 1 study in Chinses subjects with advanced solid tumors. This study is in design allowing assessment of safety, tolerability, pharmacokinetics and anti-tumor activity of HS-20093 in combination with other anti-cancer agents.

A total of 5 combination-treatments will be carried out in 3 cohorts. The target population of dose escalation part is patients have progressed on or intolerant to available standard therapies, and the dose expansion part will enroll patients who have not received prior treatment for advanced/metastatic disease.

All patients will be carefully followed for adverse events during the study treatment and for 90 days after the last dose of study drug. Subjects will be permitted to continue therapy with assessments for progression if the product is well tolerated and sustained clinical benefit exists.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Solid Tumor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Inclusion Criteria

* At least age of 18 years at screening;
* Histologically or cytologically confirmed, locally advanced or metastatic solid tumors

1. Dose escalation part will enroll advanced solid tumor for which standard treatment has proven ineffective or unavailable or intolerable.
2. Dose expansion part will enroll patients who have not received prior treatment for advanced/metastatic disease.
* least one extra-cranial measurable lesion according to RECIST 1
* Agree to provide fresh or archival tumor tissue
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0\~1
* Life expectancy \>= 12 weeks
* Agree to use medically accepted methods of contraception
* Men or women should be using adequate contraceptive measures throughout the study;
* Females subjects must not be pregnant at screening or have evidence of non-childbearing potential
* Signed and dated Informed Consent Form

Exclusion Criteria

* Any of the following would exclude the subject from participation in the study:

treatment with any of the following: Previous or current treatment with B7-H3 targeted therapy Intolerable for any PD-L1 inhibitor, cetuximab, enzalutamide and cisplatin/ carboplatin Cytotoxic chemotherapy, investigational agents and anticancer drugs within 14 days prior to the first scheduled dose of HS-20093 Prior treatment with a monoclonal antibody within 28 days prior to the first scheduled dose of HS-20093 Radiotherapy with a limited field of radiation for palliation within 2 weeks, or patients received more than 30% of the bone marrow irradiation, or large-scale radiotherapy within 4 weeks prior to the first scheduled dose of HS-20093 Major surgery within 4 weeks prior to the first scheduled dose of HS-20093

* Subjects with previous or concurrent malignancies
* Inadequate bone marrow reserve or organ dysfunction
* Evidence of cardiovascular risk
* Evidence of current severe or uncontrolled systemic diseases
* Evidence of mucosal or internal bleeding within 1 month prior to the first scheduled dose of HS-20093
* Known active infection requiring antibodies treatment within 2 weeks, or severe infection within 4 weeks prior to the first scheduled dose of HS-20093
* Subjects with current infectious diseases
* History of neuropathy or mental disorders
* Pregnant or lactating female
* History of severe hypersensitivity reaction, severe infusion reaction or idiosyncrasy to drugs chemically related to HS-20093 or any of the components of HS-20093
* Unlikely to comply with study procedures, restrictions, and requirements in the opinion of the investigator
* Any disease or condition that, in the opinion of the investigator, would compromise subject safety or interfere with study assessments

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No